Floatz logo

Mcla-158

Esophageal Cancer

Merus B.V.monoclonal_antibodyPhase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

108 Active assets in the Esophageal Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 4BB
Epirubicin
Sutro Biopharma, Inc.
Phase 3B
Pembrolizumab
Essen Biotech
Phase 3B
Cyclophosphamide
Sutro Biopharma, Inc.
Phase 3B
Capecitabine
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2B

View all 50 →

Same molecule, other indications

Mcla-158 is also rated in:

Gastroesophageal-junction CancerDormant
CC
Indicative ·
47 / 100
View asset →
Advanced/Metastatic Solid TumorsDormant
CC
Indicative ·
45 / 100
View asset →
HNSCCDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →